AN2 Therapeutics Inc
NASDAQ:ANTX
Cash Flow Statement
Cash Flow Statement
AN2 Therapeutics Inc
| Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||
| Net Income |
(41)
|
(49)
|
(54)
|
(60)
|
(65)
|
(66)
|
(65)
|
(61)
|
(51)
|
(45)
|
(37)
|
(34)
|
|
| Stock-Based Compensation |
4
|
6
|
7
|
8
|
8
|
5
|
5
|
5
|
8
|
8
|
8
|
7
|
|
| Other Non-Cash Items |
4
|
5
|
5
|
6
|
6
|
5
|
5
|
5
|
5
|
5
|
6
|
5
|
|
| Change in Working Capital |
4
|
5
|
7
|
10
|
6
|
1
|
(1)
|
(5)
|
(3)
|
(2)
|
(4)
|
(1)
|
|
| Cash from Operating Activities |
(33)
N/A
|
(38)
-15%
|
(42)
-8%
|
(44)
-6%
|
(53)
-21%
|
(59)
-11%
|
(61)
-3%
|
(61)
0%
|
(49)
+19%
|
(42)
+15%
|
(35)
+16%
|
(30)
+16%
|
|
| Investing Cash Flow | |||||||||||||
| Other Items |
(22)
|
(25)
|
23
|
(38)
|
(43)
|
(28)
|
(19)
|
61
|
55
|
38
|
27
|
15
|
|
| Cash from Investing Activities |
(22)
N/A
|
(25)
-14%
|
23
N/A
|
(38)
N/A
|
(43)
-15%
|
(28)
+36%
|
(19)
+31%
|
61
N/A
|
55
-11%
|
38
-31%
|
27
-28%
|
15
-45%
|
|
| Financing Cash Flow | |||||||||||||
| Net Issuance of Common Stock |
70
|
7
|
19
|
85
|
85
|
85
|
66
|
0
|
0
|
0
|
0
|
0
|
|
| Other |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
70
N/A
|
7
-90%
|
19
+161%
|
85
+343%
|
85
0%
|
85
+0%
|
66
-22%
|
0
-100%
|
0
+745%
|
0
-77%
|
0
N/A
|
0
+31%
|
|
| Change in Cash | |||||||||||||
| Net Change in Cash |
15
N/A
|
(56)
N/A
|
0
N/A
|
4
+1 810%
|
(12)
N/A
|
(2)
+83%
|
(14)
-596%
|
0
N/A
|
6
+1 333%
|
(4)
N/A
|
(8)
-95%
|
(14)
-82%
|
|
| Free Cash Flow | |||||||||||||
| Free Cash Flow |
(33)
N/A
|
(38)
-15%
|
(42)
-8%
|
(44)
-6%
|
(53)
-21%
|
(59)
-11%
|
(61)
-3%
|
(61)
0%
|
(49)
+19%
|
(42)
+15%
|
(35)
+16%
|
(30)
+16%
|
|